Tarsus Pharmaceuticals (NASDAQ:TARS – Get Free Report) had its price objective lifted by equities researchers at Barclays from $60.00 to $62.00 in a research note issued on Monday,Benzinga reports. The firm currently has an “overweight” rating on the stock. Barclays‘s price objective points to a potential upside of 21.43% from the stock’s previous close.
Other research analysts have also issued research reports about the company. Oppenheimer raised their price objective on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an “outperform” rating in a report on Wednesday, January 22nd. The Goldman Sachs Group increased their price objective on shares of Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a “neutral” rating in a report on Friday, November 15th. One equities research analyst has rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Tarsus Pharmaceuticals currently has an average rating of “Buy” and an average price target of $56.00.
Check Out Our Latest Analysis on TARS
Tarsus Pharmaceuticals Stock Down 0.8 %
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in TARS. R Squared Ltd purchased a new stake in shares of Tarsus Pharmaceuticals in the 4th quarter valued at $53,000. Baader Bank Aktiengesellschaft acquired a new stake in shares of Tarsus Pharmaceuticals during the fourth quarter worth about $249,000. FMR LLC increased its stake in Tarsus Pharmaceuticals by 236.6% during the 3rd quarter. FMR LLC now owns 5,032 shares of the company’s stock worth $166,000 after buying an additional 3,537 shares during the period. Bleakley Financial Group LLC acquired a new stake in Tarsus Pharmaceuticals during the 4th quarter worth approximately $323,000. Finally, SG Americas Securities LLC boosted its position in Tarsus Pharmaceuticals by 87.5% in the 3rd quarter. SG Americas Securities LLC now owns 7,242 shares of the company’s stock valued at $238,000 after buying an additional 3,379 shares during the period. 90.01% of the stock is currently owned by institutional investors and hedge funds.
About Tarsus Pharmaceuticals
Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.
Recommended Stories
- Five stocks we like better than Tarsus Pharmaceuticals
- Short Selling – The Pros and Cons
- Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]
- What is the Shanghai Stock Exchange Composite Index?
- What Does the Future Hold for Eli Lilly?
- What is a Bond Market Holiday? How to Invest and Trade
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
Receive News & Ratings for Tarsus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tarsus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.